Novanta Management
Management criteria checks 4/4
Novanta's CEO is Matthijs Glastra, appointed in Sep 2016, has a tenure of 8.83 years. total yearly compensation is $8.78M, comprised of 9.4% salary and 90.6% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth $17.78M. The average tenure of the management team and the board of directors is 3.3 years and 4.2 years respectively.
Key information
Matthijs Glastra
Chief executive officer
US$8.8m
Total compensation
| CEO salary percentage | 9.42% |
| CEO tenure | 8.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Jun 16
Returns At Novanta (NASDAQ:NOVT) Appear To Be Weighed Down
May 20Here's Why Novanta (NASDAQ:NOVT) Can Manage Its Debt Responsibly
May 03Should You Think About Buying Novanta Inc. (NASDAQ:NOVT) Now?
Apr 19Novanta: A Trusted Yet Premium Technology Partner
Apr 06Novanta Inc.'s (NASDAQ:NOVT) Stock Retreats 27% But Earnings Haven't Escaped The Attention Of Investors
Apr 05There May Be Some Bright Spots In Novanta's (NASDAQ:NOVT) Earnings
Mar 05Novanta (NASDAQ:NOVT) Has Some Way To Go To Become A Multi-Bagger
Feb 09Is Novanta (NASDAQ:NOVT) A Risky Investment?
Jan 24Should You Investigate Novanta Inc. (NASDAQ:NOVT) At US$151?
Jan 07Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Jan 01Novanta Inc.'s (NASDAQ:NOVT) Business Is Yet to Catch Up With Its Share Price
Dec 21Novanta (NASDAQ:NOVT) May Have Issues Allocating Its Capital
Oct 15What You Can Learn From Novanta Inc.'s (NASDAQ:NOVT) P/S
Sep 12Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Sep 02
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.Is It Too Late To Consider Buying Novanta Inc. (NASDAQ:NOVT)?
Aug 24Novanta Inc.'s (NASDAQ:NOVT) Intrinsic Value Is Potentially 21% Below Its Share Price
Aug 02Novanta (NASDAQ:NOVT) Might Be Having Difficulty Using Its Capital Effectively
Jun 22Does Novanta (NASDAQ:NOVT) Have A Healthy Balance Sheet?
May 30Investors Still Waiting For A Pull Back In Novanta Inc. (NASDAQ:NOVT)
May 08Novanta (NASDAQ:NOVT) Has Some Way To Go To Become A Multi-Bagger
Feb 24Does Novanta (NASDAQ:NOVT) Have A Healthy Balance Sheet?
Feb 05Getting In Cheap On Novanta Inc. (NASDAQ:NOVT) Is Unlikely
Dec 29Why Novanta Inc. (NASDAQ:NOVT) Could Be Worth Watching
Nov 20Here's Why We Think Novanta (NASDAQ:NOVT) Is Well Worth Watching
Nov 01Does This Valuation Of Novanta Inc. (NASDAQ:NOVT) Imply Investors Are Overpaying?
Oct 19Novanta (NASDAQ:NOVT) Seems To Use Debt Quite Sensibly
Sep 21Return Trends At Novanta (NASDAQ:NOVT) Aren't Appealing
Sep 06What Does Novanta Inc.'s (NASDAQ:NOVT) Share Price Indicate?
Aug 19Here's Why We Think Novanta (NASDAQ:NOVT) Is Well Worth Watching
Jul 16Slowing Rates Of Return At Novanta (NASDAQ:NOVT) Leave Little Room For Excitement
Jun 06These 4 Measures Indicate That Novanta (NASDAQ:NOVT) Is Using Debt Reasonably Well
May 16Should You Investigate Novanta Inc. (NASDAQ:NOVT) At US$156?
Apr 13Here's Why We Think Novanta (NASDAQ:NOVT) Is Well Worth Watching
Mar 29Investors Met With Slowing Returns on Capital At Novanta (NASDAQ:NOVT)
Feb 27These 4 Measures Indicate That Novanta (NASDAQ:NOVT) Is Using Debt Safely
Feb 12Is Novanta Inc. (NASDAQ:NOVT) Potentially Undervalued?
Jan 12We Ran A Stock Scan For Earnings Growth And Novanta (NASDAQ:NOVT) Passed With Ease
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 28 2025 | n/a | n/a | US$71m |
| Dec 31 2024 | US$9m | US$826k | US$64m |
| Sep 27 2024 | n/a | n/a | US$60m |
| Jun 28 2024 | n/a | n/a | US$62m |
| Mar 29 2024 | n/a | n/a | US$69m |
| Dec 31 2023 | US$8m | US$784k | US$73m |
| Sep 29 2023 | n/a | n/a | US$76m |
| Jun 30 2023 | n/a | n/a | US$77m |
| Mar 31 2023 | n/a | n/a | US$73m |
| Dec 31 2022 | US$7m | US$731k | US$74m |
| Sep 30 2022 | n/a | n/a | US$73m |
| Jul 01 2022 | n/a | n/a | US$64m |
| Apr 01 2022 | n/a | n/a | US$58m |
| Dec 31 2021 | US$12m | US$690k | US$50m |
| Oct 01 2021 | n/a | n/a | US$49m |
| Jul 02 2021 | n/a | n/a | US$44m |
| Apr 02 2021 | n/a | n/a | US$44m |
| Dec 31 2020 | US$5m | US$625k | US$45m |
| Oct 02 2020 | n/a | n/a | US$41m |
| Jul 03 2020 | n/a | n/a | US$42m |
| Apr 03 2020 | n/a | n/a | US$40m |
| Dec 31 2019 | US$4m | US$640k | US$41m |
| Sep 27 2019 | n/a | n/a | US$43m |
| Jun 28 2019 | n/a | n/a | US$56m |
| Mar 29 2019 | n/a | n/a | US$57m |
| Dec 31 2018 | US$4m | US$581k | US$51m |
Compensation vs Market: Matthijs's total compensation ($USD8.78M) is about average for companies of similar size in the US market ($USD7.50M).
Compensation vs Earnings: Matthijs's compensation has been consistent with company performance over the past year.
CEO
Matthijs Glastra (56 yo)
Mr. Matthijs Glastra serves as Independent Director at IDEX Corporation from February 21, 2025. He has been the Chief Executive Officer and Director of Novanta Inc. since September 1, 2016 and serves as it...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 8.8yrs | US$8.78m | 0.39% $ 17.8m | |
| Chief Financial Officer | 14.3yrs | US$3.91m | 0.35% $ 16.2m | |
| Chief Accounting Officer & Corporate Controller | less than a year | no data | 0.022% $ 1.0m | |
| Corporate Finance Leader & IR | no data | no data | no data | |
| Chief Information Officer & Chief Information Security Officer | 4.5yrs | no data | no data | |
| Senior Vice President of Corporate Development | 1.7yrs | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Co-Chief Operating Officer of Automation Enabling Technologies | 3.3yrs | no data | 0.037% $ 1.7m | |
| Co-Chief Operating Officer of Medical Solutions | less than a year | no data | no data | |
| Group President of Medical Solutions | 7.3yrs | no data | no data |
Experienced Management: NOVT's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 8.8yrs | US$8.78m | 0.39% $ 17.8m | |
| Chairman Emeritus | 4.2yrs | US$233.48k | no data | |
| Independent Director | 3yrs | US$277.15k | 0.0060% $ 273.2k | |
| Independent Director | 1yr | US$126.63k | 0.0016% $ 72.8k | |
| Independent Director | 3.1yrs | US$277.45k | 0.0062% $ 281.9k | |
| Independent Lead Director | 7.2yrs | US$317.45k | 0.013% $ 575.2k | |
| Independent Director | 4.2yrs | US$302.45k | 0.0073% $ 333.6k | |
| Independent Director | 13.1yrs | US$282.45k | 0.0042% $ 190.4k | |
| Independent Director | 1.2yrs | US$173.47k | 0.0023% $ 103.9k | |
| Independent Director | 5.2yrs | US$282.45k | 0.0090% $ 410.0k |
Experienced Board: NOVT's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/27 11:40 |
| End of Day Share Price | 2025/07/25 00:00 |
| Earnings | 2025/03/28 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novanta Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Mason | Baird |
| Ishan Majumdar | Baptista Research |
| Andrew Buscaglia | Berenberg |